Keyphrases
Bortezomib
100%
Protease Inhibitors
100%
Lymphocytes
100%
Apoptosis
100%
Chronic Lymphocytic Leukemia
100%
Inhibitor of Apoptosis Proteins
30%
Cell Death
20%
Phase II Clinical Trial
20%
Chronic Lymphocytic Leukemia Cells
20%
Flow Cytometry
10%
Mitochondria
10%
Mechanism of Action
10%
Phase III Clinical Trial
10%
Induced Apoptosis
10%
Positive Control
10%
Cytochrome c (Cyt c)
10%
DNA Fragmentation
10%
Caspase Activation
10%
Apoptosis-inducing Factor
10%
Immunoblotting
10%
Pro-apoptotic
10%
Cancer Therapy
10%
Apoptotic Activity
10%
Fludarabine
10%
Fludarabine-refractory
10%
Downstream Effects
10%
Refractory Patients
10%
Propidium Iodide Staining
10%
Fluorogenic Substrate
10%
Cleavage Assay
10%
Substrate Cleavage
10%
Leukemia Lymphocytes
10%
Mitochondrial Factor
10%
Acid Inhibitor
10%
Peptide Boronic Acids
10%
Pharmacology, Toxicology and Pharmaceutical Science
Bortezomib
100%
Chronic Lymphatic Leukemia
100%
Proteasome Inhibitor
100%
Clinical Trial
20%
Fludarabine
20%
Inhibitor of Apoptosis Protein
20%
Malignant Neoplasm
10%
Propidium Iodide
10%
Flow Cytometry
10%
Western Blot
10%
Glucocorticoid
10%
Cytochrome C
10%
Caspase
10%
Proteasome
10%
Apoptosis Inducing Factor
10%
Boronic Acid Derivative
10%
Apoptosis Inhibitor
10%